Literature DB >> 18263800

Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.

Michael M Tunney1, Tyler R Field, Thomas F Moriarty, Sheila Patrick, Gerd Doering, Marianne S Muhlebach, Matthew C Wolfgang, Richard Boucher, Deirdre F Gilpin, Andrew McDowell, J Stuart Elborn.   

Abstract

RATIONALE: Pulmonary infection in cystic fibrosis (CF) is polymicrobial and it is possible that anaerobic bacteria, not detected by routine aerobic culture methods, reside within infected anaerobic airway mucus.
OBJECTIVES: To determine whether anaerobic bacteria are present in the sputum of patients with CF.
METHODS: Sputum samples were collected from clinically stable adults with CF and bronchoalveolar lavage fluid (BALF) samples from children with CF. Induced sputum samples were collected from healthy volunteers who did not have CF. All samples were processed using anaerobic bacteriologic techniques and bacteria within the samples were quantified and identified.
MEASUREMENTS AND MAIN RESULTS: Anaerobic species primarily within the genera Prevotella, Veillonella, Propionibacterium, and Actinomyces were isolated in high numbers from 42 of 66 (64%) sputum samples from adult patients with CF. Colonization with Pseudomonas aeruginosa significantly increased the likelihood that anaerobic bacteria would be present in the sputum. Similar anaerobic species were identified in BALF from pediatric patients with CF. Although anaerobes were detected in induced sputum samples from 16 of 20 volunteers, they were present in much lower numbers and were generally different species compared with those detected in CF sputum. Species-dependent differences in the susceptibility of the anaerobes to antibiotics with known activity against anaerobes were apparent with all isolates susceptible to meropenem.
CONCLUSIONS: A range of anaerobic species are present in large numbers in the lungs of patients with CF. If these anaerobic bacteria are contributing significantly to infection and inflammation in the CF lung, informed alterations to antibiotic treatment to target anaerobes, in addition to the primary infecting pathogens, may improve management.

Entities:  

Mesh:

Year:  2008        PMID: 18263800     DOI: 10.1164/rccm.200708-1151OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  175 in total

1.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

Review 2.  Spectrum of viral infections in patients with cystic fibrosis.

Authors:  H Frickmann; S Jungblut; T O Hirche; U Groß; M Kuhns; A E Zautner
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-09-10

3.  Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis.

Authors:  William G Flight; Ann Smith; Christopher Paisey; Julian R Marchesi; Matthew J Bull; Phillip J Norville; Ken J Mutton; A Kevin Webb; Rowland J Bright-Thomas; Andrew M Jones; Eshwar Mahenthiralingam
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

Review 4.  The role of the bacterial microbiome in lung disease.

Authors:  Robert P Dickson; John R Erb-Downward; Gary B Huffnagle
Journal:  Expert Rev Respir Med       Date:  2013-06       Impact factor: 3.772

5.  Comparing the microbiota of the cystic fibrosis lung and human gut.

Authors:  Geraint B Rogers; Mary P Carroll; Lucas R Hoffman; Alan W Walker; David A Fine; Kenneth D Bruce
Journal:  Gut Microbes       Date:  2010-01-29

Review 6.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

7.  A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients.

Authors:  Christopher D Sibley; Michael D Parkins; Harvey R Rabin; Kangmin Duan; Jens C Norgaard; Michael G Surette
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-23       Impact factor: 11.205

8.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 9.  Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy.

Authors:  Edith T Zemanick; J Kirk Harris; Steven Conway; Michael W Konstan; Bruce Marshall; Alexandra L Quittner; George Retsch-Bogart; Lisa Saiman; Frank J Accurso
Journal:  J Cyst Fibros       Date:  2009-10-14       Impact factor: 5.482

10.  Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.

Authors:  Lucas R Hoffman; Anthony R Richardson; Laura S Houston; Hemantha D Kulasekara; Willm Martens-Habbena; Mikkel Klausen; Jane L Burns; David A Stahl; Daniel J Hassett; Ferric C Fang; Samuel I Miller
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.